サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1663452

OTC鎮痛薬の世界市場：薬剤の種類別・投与経路別・流通チャネル別・用途別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)

Over-the-Counter (OTC) Pain Medication Market, By Drug Type, By Route of Administration, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 322 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
OTC鎮痛薬の世界市場：薬剤の種類別・投与経路別・流通チャネル別・用途別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)
出版日: 2025年02月04日
発行: AnalystView Market Insights
ページ情報: 英文 322 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

OTC鎮痛薬の市場規模は2024年に289億4,260万米ドルとなり、2025年から2032年にかけてCAGR 4.20%で拡大しました。

さらに、ライフスタイルの変化や多忙なスケジュールによってストレスレベルが上昇した結果、頭痛、腰痛、筋肉痛を経験する人が増えています。その結果、処方箋薬を使わずに自己治療する傾向が強まっています。さらに、服用回数を減らし、製品の有効性を高める製剤革新により、市販薬に対する消費者の信頼も高まっています。今後数年間は、代替治療の利用可能性や鎮痛薬の悪影響に対する意識の高まりにより、市場の成長が制約される可能性があります。

OTC鎮痛薬の市場力学

世界の慢性疾患の頻度増加

OTC鎮痛薬市場は、世界の慢性疾患の頻度増加により劇的に成長しています。関節炎、腰痛、片頭痛、頭痛など、長期的な疼痛管理を必要とする慢性疾患の数は着実に増加しています。世界中で60%近くの人が慢性的な痛みの問題を経験していると考えられています。慢性痛の可能性は、寿命の延長がもたらす加齢に関連した身体的障害の蔓延によって高まっています。労働力の高齢化、多忙な生活、過労、運動不足もこの問題を悪化させています。一般用医薬品 (OTC) は手軽に入手でき、価格も手ごろで、処方箋を必要としないため、慢性疼痛を抱える人々は、一時的あるいは長期的な緩和を求めてOTCに頼ることが多いです。薬局によれば、イブプロフェン、アセトアミノフェン、外用ジェルやクリームなどで構成される有名な商品の需要が増加しているといいます。処方箋鎮痛薬も一般的に使用されていますが、中毒、耐性、副作用の心配から、OTC薬がより魅力的な選択肢になりつつあります。さらに、オピオイドやその他の制限された麻薬の過剰処方を防ぐため、医師は軽度から中等度の痛みに対する最初の治療選択肢としてOTC医薬品を勧めています。慢性疾患が世界的に蔓延するにつれ、一般用医薬品が疼痛治療に使用される頻度が高まることが予想されます。

OTC鎮痛薬市場：主な考察

弊社リサーチアナリストの分析によると、世界市場は予測期間 (2025-2032年) に約4.20%のCAGRで毎年成長すると予測されます。

薬剤の種類別では、非ステロイド性抗炎症薬カテゴリーが2024年に最大市場シェアを示すと予測されています。

流通チャネル別では、病院薬局が2024年の主要セグメントです。

地域別では、北米が2024年の売上高をリードしている

OTC鎮痛薬市場：セグメンテーション分析

OTC鎮痛薬の世界市場は、薬剤の種類、投与経路、流通チャネル、地域に基づいてセグメント化されます。

薬剤の種類に基づき、市場はアセトアミノフェン、非ステロイド性抗炎症薬、その他に分けられます。2024年には、非ステロイド性抗炎症薬カテゴリーが圧倒的な市場シェアを占めていますが、これは世界の高齢化社会において疼痛関連疾患の症例が多いためです。非ステロイド性抗炎症薬は、高齢者が頻繁に訴える腰痛、関節や筋肉の不快感、体の部位の腫れや損傷を緩和するために頻繁に使用されます。人口動態の動向によれば、平均寿命が延びるにつれて、先進国でも新興諸国でも、65歳以上の人口は今後数十年の間に劇的に増加します。高齢になると、慢性疼痛もますます一般的になります。非ステロイド性抗炎症薬 (NSAIDs) は現在、多くの家庭や薬箱の中に当たり前のように置かれていますが、これは疼痛管理を市販薬に頼る高齢者がかなり増えているためです。処方箋なしで加齢に伴う不快症状のセルフメディケーションが可能であり、その有効性が実証されていることから、広く利用されています。

投与経路別に、市場は局所・経口・非経口に分類されます。2024年、市場は経口剤カテゴリーが支配的でした。これは、特に散発的または断続的な痛みに対しては、経口錠剤が最も実用的で、人々が市販医薬品を自己投与する最も簡単な方法だからです。錠剤やカプセルを飲み込むことで、クリームやジェルを塗る不便さのない疼痛治療がどこでも可能になります。錠剤や液剤などの経口剤は、この重要な利点により、現在、自己治療の最も一般的な選択肢となっています。外出先で」使いやすいことは、外出中に頭痛や軽い筋肉の緊張を感じることがある、エネルギッシュで多忙な消費者にとって極めて重要です。内服薬は、外用薬よりも綿密な調査と試験を受けているため、安全性と効能について、顧客はより安心することができます。

OTC鎮痛薬市場：地域別分析

2024年、OTC鎮痛薬の世界市場では、北米が圧倒的な地位を占めています。OTC鎮痛薬の需要は、同地域の確立された医療システムと消費者の高い健康意識によって促進されています。人口の高齢化と慢性的な痛みの問題も、持続的な消費に影響しています。強力な薬事法は、製品の品質と安全性を保証することで消費者の信頼を促進しています。メーカーによる集中的なマーケティングや広告キャンペーンも消費を増加させます。さらに、北米のOTC鎮痛薬業界における支配的地位は、有名な製薬企業の存在と、小売店でのOTC商品の豊富な品揃えによって強化されています。

しかし、予測期間を通じて、アジア太平洋地域のCAGRが最も速いと予想されています。アジア太平洋地域は人口が多く、中間所得層が増加し、購買力が高まっているため、OTC鎮痛薬の市場は大きく発展すると予想されます。中国やインドなどの国々では、可処分所得が大幅に増加し、都市化が進んだ結果、OTC鎮痛薬の需要が増加しています。さらに、セルフメディケーションを好む文化的傾向や、一般的な病気の流行が市場の成長を加速させています。製薬会社はこの市場に注目し、拡大する消費者層に対応するため、さまざまなOTC鎮痛薬を発売しています。

OTC鎮痛薬市場：競合情勢

ジョンソン・エンド・ジョンソン、ファイザー、サノフィ、Reckitt Benckiser Group plc、バイエル、グラクソ・スミスクラインなど、多くの多国籍製薬会社がOTC鎮痛薬市場の競合環境を支配しています。ブランド品やジェネリック医薬品は、手頃な価格の代替品を提供するため、ラベル表示も重要です。サリチル酸塩、アセトアミノフェン、NSAIDなどの鎮痛製剤の市場配置は、マーケティング戦略、製品イノベーション、規制要因の影響を受けます。世界の市場動向、消費者の嗜好、流通戦略は、OTC鎮痛薬の競合に影響を与えます。企業は競争優位に立つために、いくつかの重要な対策を講じようとしています。例えば、2023年10月、ベルギーに本社を置くHyloris Pharmaceuticals社は、USFDAが強力な非オピオイド鎮痛薬Maxigesic IVを承認したと発表しました。AFTファーマシューティカルズとの提携で開発されたマキシゲシック点滴静注は、軽度から中等度の疼痛および中等度から重度の疼痛の補助剤として使用されるように設計されています。イブプロフェン300mgとパラセタモール1,000mgを配合したこの術後輸液は、麻薬に代わる治療薬となります。

最近の動向

2024年3月米国FDAは、レーザー脱毛、タトゥー、ピアス、マイクロダーマブレーションなどの美容施術前、施術中、施術後の鎮痛に使用しないよう、特定の市販外用鎮痛薬に注意を喚起しました。これらの商品を違法に宣伝したとして、6つの事業者が政府から警告書を受け取りました。

2023年1月ナチュラル・ペインリリーフ・カプセルはメデラ社の最新製品です。専門家が検証した植物由来の鎮痛薬であるメデラ・ナチュラル・ペインリリーフは、一般用医薬品 (OTC) の代替品にありがちな好ましくない副作用を伴わずに、炎症、関節のこわばり、筋肉の不快感を軽減するよう設計されています。

2022年8月：バイオ医薬品事業のMyovant Sciences社とファイザー社は、MYFEMBREE (relugolix、estradiol、norethindrone acetate) が閉経前女性の中等度から重度の子宮内膜症の痛みの治療薬として、1日1回服用する錠剤として米国食品医薬品局 (USFDA) から承認されたと発表しました。この薬剤は最長24ヵ月まで服用可能です。この承認は、子宮筋腫に起因する過多月経出血の治療にも適用され、非盲検延長試験および第3相試験のエビデンスに裏付けられています。

目次

第1章 OTC鎮痛薬市場の概要

  • 調査範囲
  • 市場推定期間

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 OTC鎮痛薬の主な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 OTC鎮痛薬市場：産業分析

  • PEST分析
  • ポーターのファイブフォース分析
  • 市場成長の見通し：マッピング
  • 規制体制の分析

第5章 OTC鎮痛薬市場：COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19以後の影響分析

第6章 OTC鎮痛薬の市場情勢

  • OTC鎮痛薬の市場シェア分析 (2024年)
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 OTC鎮痛薬市場：薬剤の種類別

  • 概要
    • セグメント別シェア分析：薬剤の種類別
    • アセトアミノフェン
    • 非ステロイド性抗炎症薬
    • その他

第8章 OTC鎮痛薬市場：投与経路別

  • 概要
    • セグメント別シェア分析：投与経路別
    • 局所
    • 経口
    • 非経口

第9章 OTC鎮痛薬市場：流通チャネル別

  • 概要
    • セグメント別シェア分析：流通チャネル別
    • 病院薬局
    • eコマース
    • 小売薬局
    • 在宅医療
    • その他

第10章 OTC鎮痛薬市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋 (APAC)
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 韓国
    • 日本
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析：OTC鎮痛薬業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Johnson &Johnson
    • Pfizer Inc.
    • Sanofi SA
    • Reckitt Benckiser Group plc
    • Bayer AG
    • GlaxoSmithKline plc
    • Novartis AG
    • Perrigo Company plc
    • Takeda Pharmaceutical Company Limited
    • Lupin Limited
    • Sun Pharmaceutical Industries Ltd.
    • Alkem Laboratories Ltd.
    • Cipla Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Glenmark Pharmaceuticals Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Boehringer Ingelheim International GmbH
    • Others

第12章 AnalystViewの全方位的分析

目次
Product Code: ANV4606

REPORT HIGHLIGHT

Over-the-Counter (OTC) Pain Medication Market size was valued at US$ 28,942.6 Million in 2024, expanding at a CAGR of 4.20% from 2025 to 2032.

Over-the-counter (OTC) medications are those that licensed pharmacists dispense without a prescription. Whether at home or work, people frequently turn to over-the-counter (OTC) pain medications to relieve even the smallest physical discomfort. Both generic and brand-name OTC pain relievers come in tablet, pill, cream, ointment, spray, and patch form. The most widely used over-the-counter painkiller, paracetamol, has no anti-inflammatory properties. In the central nervous system (CNS), paracetamol inhibits the production of prostaglandins. The first line of treatment for acute lower back pain has been suggested to be acetaminophen. Over the past few years, the market for over-the-counter painkillers has shown encouraging trends. OTC painkiller demand has been mostly driven by the world's growing population as well as the ageing population that is more susceptible to arthritis and joint pain.

Furthermore, people are experiencing increased headaches, back pain, and muscle aches as a result of elevated stress levels brought on by changing lifestyles and busy schedules. As a result, the tendency to self-medicate without prescription medications has grown. In addition, consumer confidence in over-the-counter medicines has increased due to formulation innovations that decrease dosage frequency and increase product effectiveness. In the upcoming years, the market's growth may be constrained by the availability of substitute treatment options and rising awareness of the negative effects of painkillers.

Over-the-Counter (OTC) Pain Medication Market- Market Dynamics

Increasing frequency of chronic illnesses worldwide

The market for over-the-counter (OTC) pain medications has grown dramatically as a result of the increasing frequency of chronic illnesses worldwide. The number of chronic conditions like arthritis, back pain, migraines, and headaches that need long-term pain management has been steadily increasing. Nearly 60% of people worldwide are thought to experience chronic pain issues. The likelihood of chronic pain is increased by the prevalence of age-related physical impairments brought on by longer lifespans. An ageing workforce, busy lives, an excessive workload, and a lack of physical activity are also exacerbating the issue. Because over-the-counter (OTC) drugs are readily available, reasonably priced, and do not require a prescription, people with chronic pain frequently turn to them for either episodic or long-term relief. The demand for well-known goods that comprise ibuprofen, acetaminophen, and topical gels and creams has increased, according to pharmacies. Even while prescription painkillers are also commonly used, OTC medications are becoming a more appealing option due to worries about addiction, tolerance, and adverse effects. Additionally, in order to prevent the overprescription of opioids or other restricted narcotics, doctors advise OTC pharmaceuticals as the initial therapeutic option for mild to moderate pain. Over-the-counter (OTC) drugs are expected to be used more frequently for pain treatment as chronic illnesses become more prevalent globally.

Over-the-Counter (OTC) Pain Medication Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.20% over the forecast period (2025-2032)

Based on drug type segmentation, the nonsteroidal anti-inflammatory drug category was predicted to show maximum market share in the year 2024

Based on distribution channel segmentation, hospital pharmacies were the leading segment in 2024

On the basis of region, North America was the leading revenue generator in 2024

Over-the-Counter (OTC) Pain Medication Market- Segmentation Analysis:

The Global Over-the-Counter (OTC) Pain Medication Market is segmented on the basis of Drug Type, Route of Administration, Distribution Channel, and Region.

Based on drug type, the market is divided into Acetaminophen, Nonsteroidal Anti-inflammatory Drug, and Others. In 2024, the nonsteroidal anti-inflammatory drug category held a dominant market share because of the high cases of pain-related disorders in the world's ageing population. NSAIDs are frequently used to alleviate backaches, joint and muscular discomfort, and swollen or damaged body parts that older adults frequently report. According to demographic trends, the number of people 65 and older will rise dramatically over the next several decades in both developed and developing countries as life expectancies rise. As people age, chronic pain also becomes increasingly common. NSAIDs are now commonplace in many homes and medicine cabinets due to the sizable and growing number of senior citizens who rely on over-the-counter drugs for pain management. Their extensive availability boosts their popularity for self-medication of age-related discomforts without a prescription and their demonstrated efficacy.

On the basis of the route of administration, the market is segregated into Topical, Oral, and Parenteral. In 2024, the market was dominated by the oral category. This is because, particularly for sporadic or intermittent pain, oral pills are the most practical and simplest way for people to self-administer over-the-counter pharmaceuticals. Pain treatment without the inconvenience of applying creams or gels is possible anywhere by swallowing tablets or capsules. Oral formulations, such as tablets and liquids, are now the most popular option for self-treatments due to this important benefit. Being user-friendly "on the go" is crucial for energetic, busy consumers who can have headaches or mild strained muscles while out and about. Customers can feel more secure about the safety and efficacy of oral medications because they have undergone more thorough research and testing than topical preparations.

Over-the-Counter (OTC) Pain Medication Market- Geographical Insights

In 2024, North America held a dominant position in the global market for Over-the-Counter (OTC) Pain Medication. The demand for over-the-counter (OTC) pain medications is fueled by the region's established healthcare system and high level of consumer health awareness. The ageing population and the cases of chronic pain problems also influence sustained consumption. Strong pharmaceutical laws promote consumer trust by guaranteeing the quality and safety of products. Manufacturers' intensive marketing and advertising campaigns also increase consumption. Furthermore, North America's dominant position in the over-the-counter (OTC) pain medications industry is reinforced by the existence of well-known pharmaceutical businesses and the extensive availability of OTC goods in retail establishments.

However, throughout the projected period, the Asia-Pacific region is anticipated to see the fastest CAGR. The market for over-the-counter (OTC) pain medications is expected to develop significantly in the Asia-Pacific region mainly because of its large population, growing middle class, and rising purchasing power. The demand for over-the-counter (OTC) pain medications has increased as a result of significant increases in disposable income and urbanization in nations like China and India. Additionally, a cultural propensity for self-medication and the prevalence of common illnesses have accelerated market growth. Pharmaceutical companies are focusing on this market and introducing a range of over-the-counter (OTC) painkillers to cater to the expanding consumer base.

Over-the-Counter (OTC) Pain Medication Market- Competitive Landscape:

Many multinational pharmaceutical companies, including Johnson & Johnson, Pfizer Inc., Sanofi S.A., Reckitt Benckiser Group plc, Bayer AG, GlaxoSmithKline plc, and others, dominate the competitive environment of the over-the-counter (OTC) pain medications market. Branded and generic labels are important as well since they provide affordable substitutes. The market placement of analgesic formulations, such as salicylate, acetaminophen, and NSAIDs, is influenced by marketing strategies, product innovations, and regulatory factors. Global market trends, consumer preferences, and distribution strategies influence Over-the-counter (OTC) pain medications competition. Businesses are attempting to put some important measures into place in order to get a competitive advantage. For instance, in October 2023, Belgium-based Hyloris Pharmaceuticals announced that the USFDA had approved the potent non-opioid pain reliever Maxigesic IV. Developed in partnership with AFT Pharmaceuticals, Maxigesic IV is designed to be used as an adjuvant for mild-to-moderate pain and moderate-to-severe pain. This postoperative infusion, which combines 300 mg of ibuprofen and 1,000 mg of paracetamol, offers an alternative to narcotic drugs.

Recent Development

March 2024: Certain over-the-counter topical analgesics have been cautioned by the U.S. FDA not to be used for pain relief prior to, during, or following cosmetic procedures such as laser hair removal, tattooing, piercing, and microdermabrasion. Six businesses received warning letters from the government for unlawfully promoting these goods.

January 2023: Natural Pain Relief capsules are Medterra's newest offering. A professionally validated plant-based pain reliever, Medterra Natural Pain Relief is designed to reduce inflammation, joint stiffness, and muscular discomfort without the unfavourable side effects that are frequently connected to over-the-counter (OTC) alternatives.

August 2022: The biopharmaceutical business Myovant Sciences and Pfizer announced that MYFEMBREE (relugolix, estradiol, and norethindrone acetate) was approved by the USFDA as a once-daily pill for the treatment of moderate to severe endometriosis pain in premenopausal women. The medication can be taken for up to 24 months. The clearance also covers treatment for excessive menstrual bleeding caused by uterine fibroids, and it is backed by evidence from an open-label extension study and Phase 3 trials.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL OVER-THE-COUNTER (OTC) PAIN MEDICATION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Johnson & Johnson
  • Pfizer Inc.
  • Sanofi S.A.
  • Reckitt Benckiser Group plc
  • Bayer AG
  • GlaxoSmithKline plc
  • Novartis AG
  • Perrigo Company plc
  • Takeda Pharmaceutical Company Limited
  • Lupin Limited
  • Sun Pharmaceutical Industries Ltd.
  • Alkem Laboratories Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Others

GLOBAL OVER-THE-COUNTER (OTC) PAIN MEDICATION MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Acetaminophen
  • Nonsteroidal Anti-inflammatory Drug
  • Others

GLOBAL OVER-THE-COUNTER (OTC) PAIN MEDICATION MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Topical
  • Oral
  • Parenteral

GLOBAL OVER-THE-COUNTER (OTC) PAIN MEDICATION MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • E-commerce
  • Retail Pharmacies
  • Home Care
  • Others

GLOBAL OVER-THE-COUNTER (OTC) PAIN MEDICATION MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Over-the-Counter (OTC) Pain Medication Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Over-the-Counter (OTC) Pain Medication Market Snippet by Drug Type
    • 2.1.2. Over-the-Counter (OTC) Pain Medication Market Snippet by Route of Administration
    • 2.1.3. Over-the-Counter (OTC) Pain Medication Market Snippet by Distribution Channel
    • 2.1.4. Over-the-Counter (OTC) Pain Medication Market Snippet by Country
    • 2.1.5. Over-the-Counter (OTC) Pain Medication Market Snippet by Region
  • 2.2. Competitive Insights

3. Over-the-Counter (OTC) Pain Medication Key Market Trends

  • 3.1. Over-the-Counter (OTC) Pain Medication Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Over-the-Counter (OTC) Pain Medication Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Over-the-Counter (OTC) Pain Medication Market Opportunities
  • 3.4. Over-the-Counter (OTC) Pain Medication Market Future Trends

4. Over-the-Counter (OTC) Pain Medication Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Over-the-Counter (OTC) Pain Medication Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Over-the-Counter (OTC) Pain Medication Market Landscape

  • 6.1. Over-the-Counter (OTC) Pain Medication Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Over-the-Counter (OTC) Pain Medication Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
    • 7.1.2. Acetaminophen
    • 7.1.3. Nonsteroidal Anti-inflammatory Drug
    • 7.1.4. Others

8. Over-the-Counter (OTC) Pain Medication Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 8.1.2. Topical
    • 8.1.3. Oral
    • 8.1.4. Parenteral

9. Over-the-Counter (OTC) Pain Medication Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. E-commerce
    • 9.1.4. Retail Pharmacies
    • 9.1.5. Home Care
    • 9.1.6. Others

10. Over-the-Counter (OTC) Pain Medication Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Over-the-Counter (OTC) Pain Medication Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Over-the-Counter (OTC) Pain Medication Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Over-the-Counter (OTC) Pain Medication Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Over-the-Counter (OTC) Pain Medication Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Over-the-Counter (OTC) Pain Medication Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Over-the-Counter (OTC) Pain Medication Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Johnson & Johnson
    • 11.2.2. Pfizer Inc.
    • 11.2.3. Sanofi S.A.
    • 11.2.4. Reckitt Benckiser Group plc
    • 11.2.5. Bayer AG
    • 11.2.6. GlaxoSmithKline plc
    • 11.2.7. Novartis AG
    • 11.2.8. Perrigo Company plc
    • 11.2.9. Takeda Pharmaceutical Company Limited
    • 11.2.10. Lupin Limited
    • 11.2.11. Sun Pharmaceutical Industries Ltd.
    • 11.2.12. Alkem Laboratories Ltd.
    • 11.2.13. Cipla Ltd.
    • 11.2.14. Dr. Reddy's Laboratories Ltd.
    • 11.2.15. Glenmark Pharmaceuticals Ltd.
    • 11.2.16. Teva Pharmaceutical Industries Ltd.
    • 11.2.17. Boehringer Ingelheim International GmbH
    • 11.2.18. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us